Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
SymBiosis Capital Partners, LLC (CIK 2006045) reported $52.8M across 6 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: EVMN ($29.4M, 55.80%), IVA ($13.1M, 24.76%), WVE ($5.4M, 10.30%), RANI ($2.7M, 5.11%), CLNN ($2.1M, 4.03%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune, Inc. | $29.4M | 55.80% | 1.3M | Hold |
| 2 | IVA | Inventiva S.A. | $13.1M | 24.76% | 2.4M | Trimmed |
| 3 | WVE | Wave Life Sciences Ltd. | $5.4M | 10.30% | 750,000 | New |
| 4 | RANI | Rani Therapeutics Holdings, Inc. | $2.7M | 5.11% | 3.7M | Trimmed |
| 5 | CLNN | Clene Nanomedicine Inc. | $2.1M | 4.03% | 431,094 | Trimmed |
| 6 | AARD | Aardvark Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
| 7 | AMPG | Aldeyra Therapeutics Inc | $0 | 0.00% | 0 | Exited |
| 8 | GBIO | Generation Bio Co | $0 | 0.00% | 0 | Exited |
| 9 | NUVB | Nuvation Bio Inc | $0 | 0.00% | 0 | Exited |
| 10 | PGEN | Precigen Inc | $0 | 0.00% | 0 | Exited |
| 11 | VSTM | Verastem Inc | $0 | 0.00% | 0 | Exited |
| 12 | SRZNW | Surrozen, Inc. | $2,400 | 0.00% | 150,000 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31